New cocktail therapy aims to tackle tough sarcoma
NCT ID NCT07205185
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This phase 2 trial is testing a combination of an experimental immunotherapy (epalrotokewali) with chemotherapy (eribulin), a targeted drug (anlotinib), and radiation for people with advanced soft tissue sarcoma that has worsened after initial treatment. The study will enroll 46 participants to see if this approach can shrink tumors and control the disease. It is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA (STS) are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Epalrotokewali (QL1706) combined with eribulin, anlotinib, and radiotherapy
What this could lead to
If successful, this combination could offer a new treatment option for advanced soft tissue sarcoma that has not responded to prior therapies.
What could go wrong
This is an early-phase, single-arm trial with only 46 participants, so results may not be generalizable. The combination therapy may cause significant side effects, and there is no guarantee of improved outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.